Noel Gill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Noel Gill has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Valerie Delpech
UK Health Security Agency, London, United Kingdom
2 shared publications Achyuta Nori
Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK
1 shared publicationAj Buckton
Centre for Infections, Health Protection Agency, London, UK
1 shared publication- Alison E. Brown
UK Health Security Agency, London, United Kingdom
1 shared publication Andy Williams
Barts Health NHS Trust, St Bartholomew's Hospital, London EC1A 7BE, UK
1 shared publicationAnna Tostevin
Institute for Global Health, University College London
1 shared publication
Latest Publications
- Open Access
- 10 February 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 245-247
HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England
- 10 February 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 245-247
Open AccessHTLV seroprevalence in people using HIV pre-exposure prophylaxis in England
- Open Access
- 26 February 2018
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 217 (10) , 1522-1529
Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control
The impact of HIV pre-exposure prophylaxis (PrEP) depends on infections averted by protecting vulnerable individuals as well as infections averted by preventing transmission by those who would have been infected if not receiving PrEP. Analysis of HIV phylogenies reveals risk factors for transmission, which we examine as potential criteria for allocating PrEP. We analyzed 6912 HIV-1 partial pol sequences from men who have sex with men (MSM) in the United Kingdom combined with global reference sequences and patient-level metadata. Population genetic models were developed that adjust for stage of infection, global migration of HIV lineages, and changing incidence of infection through time. Models were extended to simulate the effects of providing susceptible MSM with PrEP. We found that young age <25 years confers higher risk of HIV transmission (relative risk = 2.52 [95% confidence interval, 2.32–2.73]) and that young MSM are more likely to transmit to one another than expected by chance. Simulated interventions indicate that 4-fold more infections can be averted over 5 years by focusing PrEP on young MSM. Concentrating PrEP doses on young individuals can avert more infections than random allocation.
- 26 February 2018
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 217 (10) , 1522-1529
Open AccessMolecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control
The impact of HIV pre-exposure prophylaxis (PrEP) depends on infections averted by protecting vulnerable individuals as well as infections averted by preventing transmission by those who would have been infected if not receiving PrEP. Analysis of HIV phylogenies reveals risk factors for transmission, which we examine as potential criteria for allocating PrEP. We analyzed 6912 HIV-1 partial pol sequences from men who have sex with men (MSM) in the United Kingdom combined with global reference sequences and patient-level metadata. Population genetic models were developed that adjust for stage of infection, global migration of HIV lineages, and changing incidence of infection through time. Models were extended to simulate the effects of providing susceptible MSM with PrEP. We found that young age <25 years confers higher risk of HIV transmission (relative risk = 2.52 [95% confidence interval, 2.32–2.73]) and that young MSM are more likely to transmit to one another than expected by chance. Simulated interventions indicate that 4-fold more infections can be averted over 5 years by focusing PrEP on young MSM. Concentrating PrEP doses on young individuals can avert more infections than random allocation.
- Open Access
- 14 October 2010
- Published by Wiley in HIV Medicine
- Vol. 12 (4) , 250-254
Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance*
Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels [95% confidence interval (CI) 15.2–83.7%; P=0.002] was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.
- 14 October 2010
- Published by Wiley in HIV Medicine
- Vol. 12 (4) , 250-254
Open AccessIncreased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance*
Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels [95% confidence interval (CI) 15.2–83.7%; P=0.002] was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.
- Open Access
- 3 April 2008
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 13 (14) , 3-4
Continuing high levels of HIV diagnoses in men who have sex with men in the United Kingdom
The latest HIV data for 2007 has recently been published for the United Kingdom (UK). During the year, an estimated 6,840 (95% confidence intervals 6,600-7,050) persons (adjusted for reporting delays) were newly diagnosed with HIV in the UK. This represents a 12% decline from a peak of new HIV diagnoses reported in 2005 (7,800). Almost all this decline in new HIV diagnoses was in HIV-infected heterosexuals from sub-Saharan Africa who were probably infected in their country of origin.
- 3 April 2008
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 13 (14) , 3-4
Open AccessContinuing high levels of HIV diagnoses in men who have sex with men in the United Kingdom
The latest HIV data for 2007 has recently been published for the United Kingdom (UK). During the year, an estimated 6,840 (95% confidence intervals 6,600-7,050) persons (adjusted for reporting delays) were newly diagnosed with HIV in the UK. This represents a 12% decline from a peak of new HIV diagnoses reported in 2005 (7,800). Almost all this decline in new HIV diagnoses was in HIV-infected heterosexuals from sub-Saharan Africa who were probably infected in their country of origin.